Rigel Pharmaceuticals develops and commercializes small-molecule drugs for immune and hematologic disorders. Its flagship product TAVALISSE (fostamatinib) is an oral SYK inhibitor used in adults with chronic immune thrombocytopenia who have not responded adequately to prior therapy. The portfolio also includes REZLIDHIA (olutasidenib) for certain IDH1-mutated acute myeloid leukemia cases. The company focuses on signaling pathways that drive autoimmune blood disorders and related rare or hard-to-treat conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 53.3 | — | 11.4 | — |
| Q2 2025 | 101.7 | — | 59.6 | — |
| Q3 2025 | 69.5 | — | 27.9 | 123.2% |
| Q4 2025 | 69.8 | — | 268.1 | 1,802.3% |
| Q1 2026 | 58.8 | 10.3% | 8.7 | -24.4% |
| Q2 2026 | 78.7 | -22.6% | 17.3 | -71% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: John B. Sanfilippo & Son, Inc. (JBSS), InMode Ltd. (INMD), Donegal Group Inc. (DGICB), Root, Inc. (ROOT), Cybin D/B/A Helus Pharma (HELP), Fox Factory Holding Corp. (FOXF)